Dear Editor, Refractory agitation (RA) is a frequent and challenging problem in patients in the pediatric intensive care unit (PICU). After exclusion of imminent hypoxia, the differential diagnosis of RA includes: (i) delirium due to the underlying critical illness, and/or (ii) withdrawal, and/or (iii) disinhibition/paradoxical arousal due to benzodiazepines [1, 2] . In most cases, haloperidol gives satisfactory results [3] , although RA may persist despite this treatment. Also benzodiazepines are often given, but may be ineffective or even contraindicated to restore patient comfort. After all, many patients in a PICU already receive or have received benzodiazepines and may have developed a certain level of tolerance. In others, benzodiazepines should be avoided because of associated disinhibition, which has particularly been observed in critically and/or terminally ill children [2] . Therefore, a rescue strategy may be needed [1] .
A possible solution for the treatment of RA is the addition of methotrimeprazine (MTZ, also known as levomepromazine or Nozinan), an aliphatic phenothiazine neuroleptic drug with a weak antipsychotic, but strong sedative effect. This classic neuroleptic is commonly used as co-medication in emergency psychiatry in adults to treat acute psychosis or mania by reducing levels of agitation, anger, and aggressiveness [4] , thereby improving comfort for all-the patient, family, and members of the multidisciplinary team. There is no literature to allow for advisory dosages of MTZ in children with RA; however, in palliative care 0.1 mg/kg IV/SC/8 h is suggested [1] . In adults, maximum dosages of t.i.d. 25-50 mg/orally/ 24 h MTZ are common. Potential, but rare side effects of MTZ include tardive dyskinesia, akathisia, neuroleptic malignant syndrome, and extrapyramidal and cholinergically mediated side effects; a contraindication is bone marrow depression [4] .
We recently used MTZ in four critically ill children presenting with RA (patient characteristics are summarized in Table 1 ). All patients initially received standard analgosedative treatment according to consensus guidelines [5] . Two patients developed delirium for which an individually titrated dosage of haloperidol remained insufficient or ineffective. A third patient suffered from therapy-resistant agitation during slowly weaning from sedation, for which several analgosedatives were We conclude that once RA still continues after adequate 24-h dosages of D2-blocking agents, the addition of MTZ by trial and error titration might be a useful option [4] . We would like to reintroduce and underscore, on the basis of empirical evidence and by analogy to what is known in adults [1, 4] , the use and effectiveness of MTZ in the treatment of RA in critically ill children in the PICU.
